SEARCH

SEARCH BY CITATION

References

  • 1
    Rapp SR, Feldman SR, Exum ML et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41:4017.
  • 2
    Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in U.S. adults: results from NHANES 2003–2004. J Am Acad Dermatol 2009; 60:21824.
  • 3
    Schmitt JM, Ford DE. Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology 2006; 213:10210.
  • 4
    Dubertret L, Mrowietz U, Ranki A et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 2006; 155:72936.
  • 5
    Smith CH, Barker JN. Psoriasis and its management. BMJ 2006; 333:3804.
  • 6
    Bewley A, Page B. Maximizing patient adherence for optimal outcomes in psoriasis. J Eur Acad Dermatol Venereol 2011; 25 (Suppl. 4):914.
  • 7
    Sawyer L, Samarasekera EJ, Wonderling D, Smith CH. Topical therapies for the treatment of localized plaque psoriasis in primary care: a cost-effectiveness analysis. Br J Dermatol 2013; 168:1095105.
  • 8
    National Clinical Guideline Centre. Psoriasis: Assessment and Management of Psoriasis. London: National Clinical Guideline Centre, 2012.
  • 9
    Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005; 331:897900.
  • 10
    Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997; 50:68391.
  • 11
    Barker JN, Griffiths CE. Combination therapy for psoriasis. Dermatol Ther 1999; 11:96103.
  • 12
    Perez A, Chen TC, Turner A et al. Efficacy and safety of topical calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis. Br J Dermatol 1996; 134:23846.
  • 13
    Fleming C, Ganslandt C, Guenther L et al. Calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of psoriasis vulgaris: a randomised, parallel group, double-blind, exploratory study. Eur J Dermatol 2010; 20:46571.
  • 14
    Kaufmann R, Bibby A, Bissonnette R et al. A new calcipotriol/betamethasone dipropionate formulation (Daivobet™) is an effective once-daily treatment for psoriasis vulgaris. Dermatology 2002; 205:38993.
  • 15
    Langley RG, Gupta A, Papp K et al. Calcipotriol plus betamethasone dipropionate gel compared with tacalcitol ointment and the gel vehicle alone in patients with psoriasis vulgaris: a randomized, controlled clinical trial. Dermatology 2011; 222:14856.
  • 16
    Medansky RS, Brody NI, Kanof NB et al. Clinical investigations of mometasone furoate – a novel nonfluorinated, topical corticosteroid. Semin Dermatol 1987; 6:94100.
  • 17
    Decroix J, Pres H, Tsankov N et al. Clobetasol propionate lotion in the treatment of moderate to severe plaque-type psoriasis. Cutis 2004; 74:2016.
  • 18
    Weinstein GD, Koo JY, Krueger GG et al. Tazarotene cream in the treatment of psoriasis: two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0·05% and 0·1% applied once daily for 12 weeks. J Am Acad Dermatol 2003; 48:7607.
  • 19
    Langner A, Verjans H, Stapór V et al. 1-α, 25-Dihydroxyvitamin D3 (calcitriol) ointment in psoriasis. J Dermatolog Treat 1992; 3:17780.
  • 20
    Langner A, Verjans H, Stapór V et al. Topical calcitriol in the treatment of chronic plaque psoriasis: a double-blind study. Br J Dermatol 1993; 128:56671.
  • 21
    Highton A, Quell J. Calcipotriene ointment 0·005% for psoriasis: a safety and efficacy study. Calcipotriene Study Group. J Am Acad Dermatol 1995; 32:6772.
  • 22
    Dubertret L, Wallach D, Souteyrand P et al. Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris. A randomized, double-blind, right/left comparative, vehicle-controlled study. J Am Acad Dermatol 1992; 27:9838.
  • 23
    Harrington CI, Goldin D, Lovell CR et al. Comparative effects of two different calcipotriol (MC 903) cream formulations versus placebo in psoriasis vulgaris. A randomised, double-blind, placebo-controlled, parallel group multi-centre study. J Eur Acad Dermatol Venereol 1996; 6:1528.
  • 24
    Papp KA, Guenther L, Boyden B et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 2003; 48:4854.
  • 25
    Guenther L, van de Kerkhof PC, Snellman E et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol 2002; 147:31623.
  • 26
    Wortzel WH. A new corticosteroid for moderate/severe dermatoses. Clin Med 1975; 82:236.
  • 27
    Sears HW. A double-blind, randomized, placebo-controlled evaluation of the efficacy and safety of hydrocortisone buteprate 0·1% cream in the treatment of psoriasis. Adv Ther 1997; 14:1409.
  • 28
    Lowe N, Feldman SR, Sherer D et al. Clobetasol propionate lotion, an efficient and safe alternative to clobetasol propionate emollient cream in subjects with moderate to severe plaque-type psoriasis. J Dermatolog Treat 2005; 16:15864.
  • 29
    Gottlieb A, Chaudhari U, Baker D et al. The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): a comparison. J Drugs Dermatol 2003; 2:2606.
  • 30
    Lebwohl M, Sherer D, Washenik K et al. A randomized, double-blind, placebo-controlled study of clobetasol propionate 0·05% foam in the treatment of nonscalp psoriasis. Int J Dermatol 2002; 41:26974.
  • 31
    Jarratt MT, Clark SD, Savin RC et al. Evaluation of the efficacy and safety of clobetasol propionate spray in the treatment of plaque-type psoriasis. Cutis 2006; 78:34854.
  • 32
    Kragballe K, Barnes L, Hamberg KJ et al. Calcipotriol cream with or without concurrent topical corticosteroid in psoriasis: tolerability and efficacy. Br J Dermatol 1998; 139:64954.
  • 33
    Ortonne P, Kaufmann R, Lecha M, Goodfield M. Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial. Dermatology 2004; 209:30813.
  • 34
    Camarasa JM, Ortonne JP, Dubertret L. Calcitriol shows greater persistence of treatment effect than betamethasone dipropionate in topical psoriasis therapy. J Dermatolog Treat 2003; 14:813.
  • 35
    Molin L. Does addition of topical calcipotriol to UVB increase the risk of irritant reactions in psoriasis? The Calcipotriol-UVB study group Acta Derm Venereol 1997; 77:4012.
  • 36
    Kragballe K, Gjertsen BT, de Hoop D et al. Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet 1991; 337:1936.
  • 37
    Cunliffe WJ, Berth-Jones J, Claudy A et al. Comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris. J Am Acad Dermatol 1992; 26:73643.
  • 38
    Douglas WS, Poulin Y, Decroix J et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol 2002; 82:1315.
  • 39
    Ruzicka T, Lorenz B. Comparison of calcipotriol monotherapy and a combination of calcipotriol and betamethasone valerate after 2 weeks’ treatment with calcipotriol in the topical therapy of psoriasis vulgaris: a multicentre, double-blind, randomized study. Br J Dermatol 1998; 138:2548.
  • 40
    Tham SN, Lun KC, Cheong WK. A comparative study of calcipotriol ointment and tar in chronic plaque psoriasis. Br J Dermatol 1994; 131:6737.
  • 41
    Alora-Palli MB, Perkins AC, Van Cott A, Kimball AB. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream. Am J Clin Dermatol 2010; 11:27583.
  • 42
    Pinheiro N. Comparative effects of calcipotriol ointment (50 μg/g) and 5% coal tar/2% allantoin/0·5% hydrocortisone cream in treating plaque psoriasis. Br J Clin Pract 1997; 51:1619.
  • 43
    Hutchinson P, Marks R, White J. The efficacy, safety and tolerance of calcitriol 3 μg/g ointment in the treatment of plaque psoriasis: a comparison with short-contact dithranol. Dermatology 2000; 201:13945.
  • 44
    Wall AR, Poyner TF, Menday AP. A comparison of treatment with dithranol and calcipotriol on the clinical severity and quality of life in patients with psoriasis. Br J Dermatol 1998; 139:100511.
  • 45
    Berth-Jones J, Chu AC, Dodd WA et al. A multicentre, parallel-group comparison of calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis. Br J Dermatol 1992; 127:26671.
  • 46
    Christensen OB, Mork N-J, Ashton R et al. Comparison of a treatment phase and a follow-up phase of short-contact dithranol and calcipotriol in outpatients with chronic plaque psoriasis. J Dermatolog Treat 1999; 10:2615.
  • 47
    Oranje AP, Marcoux D, Svensson A et al. Topical calcipotriol in childhood psoriasis. J Am Acad Dermatol 1997; 36:2038.
  • 48
    Menter A, Abramovits W, Cólon LE et al. Comparing clobetasol propionate 0·05% spray to calcipotriene 0·005% betamethasone dipropionate 0·064% ointment for the treatment of moderate to severe plaque psoriasis. J Drugs Dermatol 2009; 8:527.
  • 49
    Thawornchaisit P, Harncharoen K. A comparative study of tar and betamethasone valerate in chronic plaque psoriasis: a study in Thailand. J Med Assoc Thai 2007; 90:19972002.
  • 50
    Beutner K, Chakrabarty A, Lemke S, Yu K. An intra-individual randomized safety and efficacy comparison of clobetasol propionate 0·05% spray and its vehicle in the treatment of plaque psoriasis. J Drugs Dermatol 2006; 5:35760.
  • 51
    Bruce S, Epinette WW, Funicella T et al. Comparative study of calcipotriene (MC 903) ointment and fluocinonide ointment in the treatment of psoriasis. J Am Acad Dermatol 1994; 31:7559.
  • 52
    Jorizzo JL, Magee K, Stewart DM et al. Clobetasol propionate emollient 0.05 percent: hypothalamic-pituitary-adrenal-axis safety and four-week clinical efficacy results in plaque-type psoriasis. Cutis 1997; 60:5560.
  • 53
    Kragballe K, Noerrelund KL, Lui H et al. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol 2004; 150:116773.
  • 54
    Salmhofer W, Maier H, Soyer HP et al. Double-blind, placebo-controlled, randomized, right-left study comparing calcipotriol monotherapy with a combined treatment of calcipotriol and diflucortolone valerate in chronic plaque psoriasis. Acta Derm Venereol Suppl (Stockh) 2000; 211:58.
  • 55
    van de Kerkhof PC, van der Valk PG, Swinkels OQ et al. A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: a randomized controlled trial of supervised treatment of psoriasis vulgaris in a day-care setting. Br J Dermatol 2006; 155:8007.
  • 56
    van de Kerkhof PC, Werfel T, Haustein UF et al. Tacalcitol ointment in the treatment of psoriasis vulgaris: a multicentre, placebo-controlled, double-blind study on efficacy and safety. Br J Dermatol 1996; 135:75865.
  • 57
    Katz HI, Prawer SE, Medansky RS et al. Intermittent corticosteroid maintenance treatment of psoriasis: a double-blind multicenter trial of augmented betamethasone dipropionate ointment in a pulse dose treatment regimen. Dermatologica 1991; 183:26974.
  • 58
    Kragballe K, Austad J, Barnes L et al. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Br J Dermatol 2006; 154:115560.
  • 59
    Kragballe K, Austad J, Barnes L et al. Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the treatment of psoriasis vulgaris. Dermatology 2006; 213:31926.
  • 60
    Griffiths CE, Finlay AY, Fleming CJ et al. A randomized, investigator-masked clinical evaluation of the efficacy and safety of clobetasol propionate 0·05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis. J Dermatolog Treat 2006; 17:905.
  • 61
    Buckley C, Hoffmann V, Shapiro J et al. Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study. Dermatology 2008; 217:10713.
  • 62
    Franz TJ, Parsell DA, Halualani RM et al. Betamethasone valerate foam 0·12%: a novel vehicle with enhanced delivery and efficacy. Int J Dermatol 1999; 38:62832.
  • 63
    Franz TJ, Parsell DA, Myers JA, Hannigan JF. Clobetasol propionate foam 0·05%: a novel vehicle with enhanced delivery. Int J Dermatol 2000; 39:5358.
  • 64
    Green C, Ganpule M, Harris D et al. Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp. Br J Dermatol 1994; 130:4837.
  • 65
    Jarratt M, Breneman D, Gottlieb AB et al. Clobetasol propionate shampoo 0·05%: a new option to treat patients with moderate to severe scalp psoriasis. J Drugs Dermatol 2004; 3:36773.
  • 66
    Jemec GB, Ganslandt C, Ortonne JP et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. J Am Acad Dermatol 2008; 59:45563.
  • 67
    Klaber MR, Hutchinson PE, Pedvis-Leftick A et al. Comparative effects of calcipotriol solution (50 μg mL−1) and betamethasone 17-valerate solution (1 mg mL−1) in the treatment of scalp psoriasis. Br J Dermatol 1994; 131:67883.
  • 68
    Kragballe K, Hoffmann V, Ortonne JP et al. Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. Br J Dermatol 2009; 161:15966.
  • 69
    McKinnon C, Klaber MR. Calcipotriol (Dovonex) scalp solution in the treatment of scalp psoriasis: comparative efficacy with 1% coal tar/1% coconut oil/0·5% salicylic acid (Capasal) shampoo, and long-term experience. J Dermatolog Treat 2000; 11:218.
  • 70
    Olsen EA, Cram DL, Ellis CN et al. A double-blind, vehicle-controlled study of clobetasol propionate 0·05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. J Am Acad Dermatol 1991; 24:4437.
  • 71
    Reygagne P, Mrowietz U, Decroix J et al. Clobetasol propionate shampoo 0·05% and calcipotriol solution 0·005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis. J Dermatolog Treat 2005; 16:316.
  • 72
    Sofen H, Hudson CP, Cook-Bolden FE et al. Clobetasol propionate 0·05% spray for the management of moderate-to-severe plaque psoriasis of the scalp: results from a randomized controlled trial. J Drugs Dermatol 2011; 10:88592.
  • 73
    Tyring SK, Mendoza N, Appell M et al. A calcipotriene/betamethasone dipropionate two-compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomized, 8-week, double-blind phase of a clinical trial. Int J Dermatol 2010; 49:132833.
  • 74
    van de Kerkhof PC, Hoffmann V, Anstey A et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. Br J Dermatol 2009; 160:1706.
  • 75
    Poulin Y, Papp K, Bissonnette R et al. Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of moderate scalp psoriasis. J Dermatolog Treat 2010; 21:18592.
  • 76
    Luger TA, Cambazard F, Larsen FG et al. A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis. Dermatology 2008; 217:3218.
  • 77
    Smith DR, Bottomley JM, Auland M et al. Heterogeneity in the treatment of moderately severe scalp psoriasis in Scotland – results of a survey of Scottish health professionals. Curr Med Res Opin 2011; 27:23949.
  • 78
    British Association of Dermatologists, Primary Care Dermatology Society. Recommendations for the Initial Management of Psoriasis. London: British Association of Dermatologists, 2010.